<h4>Background</h4>Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular (CV) outcomes in patients with heart failure (HF) and type 2 diabetes. This evidence concerns the gene SLC5A2 and heart failure.